Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Link to Cantor Panel Talk
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(56)
•••
Post by Mannequinon Sep 20, 2023 9:02am
168 Views
Post# 35644945

Link to Cantor Panel Talk

Link to Cantor Panel TalkThis company is also in a Panel and has a "Register to Listen" on their very similar press release.

Why does the TH news not have this link?

https://www.newsfilecorp.com/release/181192/Satellos-to-Participate-in-the-Cantor-Fitzgerald-Global-Healthcare-Conference-2023


Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzgerald Global Healthcare Conference 2023 taking place September 26 - 28 in New York City.

Mr. Frank Gleeson, President and CEO of Satellos, will participate in a panel presentation on Wednesday, September 27, 2023, at 2:25 p.m. ET and will participate in one-on-one meetings during the conference along with Ms. Elizabeth Williams, CFO of Satellos. To access a webcast of the panel presentation live or for 90 days after the event please click here.

About Satellos Bioscience Inc.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities